The promise of antibody-oligonucleotide conjugates for neurological diseases

“To fully unlock their potential, there are a few key breakthroughs that are going to be critical.”

Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Kerstin Hofer, Science and People Lead, Roche, about the evolving application of antibody-oligonucleotide conjugates in neurology. She highlights their design, delivery challenges across the blood–brain barrier, and potential to transform CNS diseases.

Please enter your email to access content Read now